Patient info Open main menu

Bezalip Mono 400 mg tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
400 mg
Contains active substance:
Similar medicines:

Patient leaflet - Bezalip Mono 400 mg tablets

1. What Bezalip Mono is and what it is used for

Bezalip Mono belongs to a group of medicines, commonly known as fibrates. These medicines are used to lower the level of fats (lipids) in the blood. For example the fats known as triglycerides.

Bezalip Mono is used, alongside a low fat diet and other non-medical treatments such as exercise and weight loss, to lower levels of fats in the blood.

2. What you need to know before you take Bezalip Mono

Do not take Bezalip Mono:

  • if you are allergic (hypersensitive) to bezafibrate or any of the other ingredients in the tablets (see section 6).
  • if you are allergic (hypersensitive) to fibrates or have developed a sensitivity to sunlight or artificial light (e.g. sunbeds) when taking these medicines.
  • if you are taking statins (e.g. atorvastatin) and have any of the following which may increase the risk of you developing muscle disease (weakness, wasting and pain):

    • impaired kidney function
    • an underactive thyroid (hypothyroidism)
    • severe infection
    • trauma
    • surgery
    • a change in the levels of hormones or chemicals in your body (seen in a blood test)
    • a high alcohol intake.

  • if you are having dialysis.
  • if you have liver disease.
  • if you have gall bladder disease.
  • if you have nephrotic syndrome (a kidney disorder).
  • if you have impaired kidney function.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking Bezalip Mono:

  • if you have an abnormal level of fats (lipids) in your blood caused by:

    • uncontrolled type 2 diabetes mellitus
    • an underactive thyroid (hypothyroidism)
    • nephrotic syndrome (a kidney disorder)
    • an abnormal protein content in the blood
    • obstructive liver disease
    • medication
  • if you have an alcohol addiction.

    • if you have any of the following which may increase the risk of you developing muscle disease (weakness, wasting and pain):

      • impaired kidney function
      • an underactive thyroid (hypothyroidism)
      • severe infection
      • trauma
      • surgery
      • a change in the levels of hormones or chemicals in your body (seen in a blood test)
      • a high alcohol intake
      • are elderly (over 65 years old)
      • have a family history of muscle disease.

Children and adolescents

Bezalip Mono should not be used in children.

Other medicines and Bezalip Mono

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Especially:

  • coumarin-type anti-coagulants e.g. warfarin (used to prevent blood clotting).
  • antidiabetic medicines such as insulin (used in diabetes).
  • ciclosporin (used to suppress the immune system).
  • anion exchange resins such as colestyramine (used to lower cholesterol). Bezalip Mono and an anion exchange resin should not be taken within 2 hours of each other.
  • statins e.g. atorvastatin (used to lower cholesterol).
  • monoamine-oxidase inhibitors (MAOIs) e.g. phenelzine (used in depression).
  • oestrogen or medicines which contain oestrogen.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines

Bezalip Mono may make you feel dizzy. Make sure you are not affected before you drive or operate machinery.

Tests

If you have impaired kidney function, your doctor may want to monitor you regularly by carrying out tests.

Important information about some of the ingredients of Bezalip Mono

This medicine contains lactose. If you have been told you have an intolerance to some sugars, contact your doctor before taking this medicine, as it contains a type of sugar called lactose.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

3. How to take Bezalip Mono

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Swallow the tablets whole with water, after food in the morning or evening.

Bezalip Mono and an anion exchange resin should not be taken within 2 hours of each other.

The recommended dose is:

Adults: One tablet a day (400mg bezafibrate a day).

Elderly: Your doctor may reduce the dose depending on how well your kidneys are working.

Children: Not recommended.

Impaired kidney function: Do not take Bezalip Mono if you have impaired kidney function or are having dialysis.

If you take more Bezalip Mono than you should

If you (or someone else) swallow a lot of tablets at the same time, or you think a child may have swallowed any contact your nearest hospital casualty department or tell your doctor immediately. Signs of an overdose include abnormal muscle breakdown (muscle pain or weakness, swelling) which can lead to kidney problems (rhabdomyolysis).

If you forget to take Bezalip Mono

Do not take a double dose to make up for a forgotten dose. If you forget to take a dose take it as soon as you remember it and then take the next dose at the right time.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Contact your doctor immediately if you notice signs of:

  • an allergic reaction (hypersensitivity): swelling of the face, lips, tongue or throat, itchy skin rash or narrowing of the airways causing difficulty breathing or swallowing.
  • gallstones: pain in the upper abdomen or yellowing of the skin or whites of the eyes (jaundice).
  • abnormal muscle breakdown (rhabdomyolysis): muscle pain or weakness, swelling.
  • severe form of skin rash with flushing, fever, blisters or ulcers (Stevens-Johnson Syndrome)
  • severe rash involving reddening, peeling and swelling of the skin that resembles severe burns (Toxic epidermal necrolysis).

Tell your doctor if you notice any of the following side effects or notice any other effects not listed:

Common (may affect up to 1 in 10 people):

  • decreased appetite
  • stomach disorders.

Uncommon (may affect up to 1 in 100 people):

  • dizziness
  • headache
  • bloated feeling
  • feeling sick
  • diarrhoea
  • stomach pain
  • constipation
  • indigestion
  • blocked bile flow (cholestasis)
  • itching
  • pale or red irregular raised patches with severe itching (hives)
  • rash
  • sensitivity to sunlight or artificial light (e.g. sun beds)
  • hair loss (alopecia)
  • muscle weakness, cramps or pain (myalgia)
  • acute kidney failure
  • erection problems
  • changes in the levels of certain enzymes within the body (seen in a blood test)
  • increased blood levels of creatinine.

Rare (may affect up to 1 in 1000 people):

  • damage to nerve endings causing tingling, pins and needles
  • inflammation of the pancreas (pancreatitis)
  • depression
  • difficulty sleeping.

Very rare (may affect up to 1 in 10,000 people):

  • inflammation in the lungs (interstitial lung disease)
  • decreased levels of platelets in the blood causing a disorder characterised by blood spots
  • bruising and discolouring to the skin (thrombocytopenic purpura)
  • decreased levels of the red blood pigment haemoglobin
  • increased levels of certain enzymes within the body (seen in a blood test)
  • circular, irregular red patches on the skin of the hands and arms (erythema multiforme)
  • changes in the numbers and types of your blood cells.

If you notice increased bruising, nosebleeds, sore throats, infections, excessive tiredness, breathlessness on exertion or abnormal paleness of the skin, you should tell your doctor who may want you to have a blood test.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed on this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to Store Bezalip Mono

  • Keep this medicine out of the sight and reach of children
  • Do not use this medicine after the expiry date shown on the blister strip and carton. The expiry date refers to the last day of that month. The expiry date indicated refers to the product being correctly stored in the original packaging.
  • No special storage conditions.
  • If your doctor tells you to stop the treatment, take any leftover tablets to the pharmacist. Only keep them if your doctor tells you to.
  • If the tablets become discoloured or show any signs of deterioration, seek the advice of your pharmacist who will advise you what to do.
  • Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. Contents of the pack and other information

The active substance is bezafibrate. Each tablet contains 400 mg of bezafibrate. The tablets also contain lactose, povidone, sodium laurilsulfate, hypromellose, silica colloidal hydrated, magnesium stearate (E572), polymethacrylic acid esters, macrogol 10,000, talc (E553b), titanium dioxide (E171), polysorbate 80 and sodium citrate (E331). No synthetic colouring substances are present in the formulation.

What Bezalip Mono looks like and contents of the pack

Each round white film-coated, modified release tablet is marked ‘D9’ on one side and plain on the reverse. The tablets are packed in blister strips and come in cartons of 30 tablets.

Manufacturer:

Cenexi 52, Rue Marcel et Jacques Gaucher

94120 Fontenay-Sous-Bois, France

Procured within the EU

Product Licence Holder: Ecosse Pharmaceuticals Ltd.,

3 Young Place, East Kilbride, G75 0TD.

Re-packaged by: Munro Wholesale Medical Supplies Ltd.,

3 Young Place, East Kilbride G75 0TD.

PL 19065/0426

Leaflet revision date: 26.09.2022

E0426/7 05.20

If you are blind or partially sighted and require this leaflet in a different format, call 01355 574450 and ask for the Regulatory Department.

Bezalip® is a registered trade mark of Actavis Deutschland GmbH & Co. KG

POM

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLPI 19065/0426

Last revision stated in the text: 26 September 2022 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Bezalip Mono 400 mg tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Bezafibrate
Strength 400 mg
Pharmaceutical form Modified-release tablet
How is it taken Oral
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Drug group (ATC)
  1. C Cardiovascular system drugs
    1. C10 Lipid modifying agents
      1. C10A Lipid modifying agents, plain
        1. C10AB Fibrates, lipid modifying drugs, plain
          1. C10AB02 bezafibrate
Marketing authorisation PLPI 15184/0030, PLPI 19065/0426
Codes BNF 02120000

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.